首页> 外文OA文献 >Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer

【2h】

Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer

机译：用蛋白酶体抑制剂和抗雌激素的组合处理具有由P21WAF1介导的协同作用，雌激素受体阳性乳腺癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Marie Maynadier; Ilaria Basile; Audrey Gallud; Magali Gary-Bobo; Marcel Garcia;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21(WAF1) in estrogen receptor-positive breast cancer [J] . Maynadier Marie, Basile Ilaria, Gallud Audrey, Oncology reports . 2016,第2期

机译：蛋白酶体抑制剂和抗雌激素的联合治疗在雌激素受体阳性乳腺癌中具有p21（WAF1）介导的协同作用
2. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. [J] . Ikeda H, Taira N, Nogami T, Cancer science. . 2011,第11期

机译：氟司韦特和各种细胞毒剂（阿霉素，紫杉醇，多西他赛，长春瑞滨和5-氟尿嘧啶）的联合治疗在雌激素受体阳性的乳腺癌中具有协同作用。
3. In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. [J] . Bennink RJ, van Tienhoven G, Rijks LJ, The Journal of Nuclear Medicine . 2004,第1期

机译：雌激素受体阳性乳腺癌中抗雌激素治疗反应的体内预测。
4. Estrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century Personalized Prognostic and Predictive Assays [C] . Frederick L. Baehner International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009

机译：雌激素受体阳性乳腺癌：传统预测，分子病理：新的乳腺癌分类和21世纪个性化预测和预测测定
5. The SERM, arzoxifene, and the rexinoid, LG100268, cooperate to prevent estrogen receptor-positive and -negative breast cancer as well as colon cancer. [D] . Rendi, Mara H. 2004

机译：SERM，arzoxifene和类维生素LG100268共同预防雌激素受体阳性和阴性乳腺癌以及结肠癌。
6. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors [O] . M Brandão, R Caparica, D Eiger, -1

机译：雌激素受体阳性乳腺癌患者对PI3K抑制剂反应和耐药的生物标志物以及涉及PI3K抑制剂的联合疗法
7. Suppresion of estrogen receptor (ER) - positive breast cancer cells' resistance to antiestrogens by using combinations of 4-Hydrotamoxifen (OHT), a typical antiestrogen, with phosphatidylinositol 3-Kinase (PI3K) inhibitors [O] . Τσιριγώτη Χρυσούλα 2015

机译：抑制雌激素受体（ER） - 阳性乳腺癌细胞对抗雌激素的抗性通过4-Hydrotamoxifen（OHT），一种典型的抗雌激素，与磷脂酰肌醇3-激酶（pI3K）抑制剂的组合

Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅